(PharmaNewsWire.Com, November 27, 2021 ) According to a new market research RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2027, published by MarketsandMarkets™, the market is expected to reach USD 1,503.3 million by 2027 from USD 574.3 million in 2017, at a CAGR of 10.1%.
Browse 86 tables and 31 figures spread through 113 pages and in-depth TOC on "RSV Diagnostics Market"
Factors driving the growth of this market include rising burden of RSV infections, growing demand for PoC molecular diagnostic tests for the diagnosis of RSV infections, and increasing approval of RSV diagnostic kits and assays.
New technologies such as filament-based antibody detection assays, thin layer-based amperometric enzyme immunoassay (EIA), and multiplex virus testing are in the final stage of development. Furthermore, nucleic acid amplification techniques and loop-mediated isothermal amplification will soon be aligned with PoC devices. This will allow testing to be performed using a one-step kit, which will require only the addition of a patient sample. Also, the nanoparticle technology, which has the potential to bring about a four-fold improvement in viral detection as compared to RT-PCR (the current gold standard), is under development.
Similarly, plasmonic detection techniques such as localized surface plasmon resonance (LSPR) spectroscopy (which uses metallic nanomaterials by exploiting physicochemical peculiarities) are under development with PoC detection devices. This is considered as a major development as methods such as LSPR spectroscopy offer rapid diagnostics and superior sensitivity & affordability as compared to techniques such as surface-enhanced Raman spectroscopy (SERS) and PCR coupled with electrospray ionization Mass Spectrometry (PCR-ESI-MS), which are not cost-effective, cumbersome to perform, and are more limited to research purposes. In the next few years, all the above-mentioned technologies are expected to be included in commercialized diagnostic methods. This is considered as a potential growth area for players operating in the global RSV diagnostics market.
Based on region, the RSV Diagnostics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is estimated to dominate the respiratory syncytial virus diagnostic market in 2017. This is mainly due to factors such as the increasing patient base of RSV diseases, technological advancements in PoC molecular diagnostic devices, and growing healthcare expenditures.
Key players in the RSV Diagnostics Market include bioMérieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg).
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
